Servier’s $1.5 Billion Muscle Drug Fails Late-Stage Becker Muscular Dystrophy Trial

A pivotal study of Servier’s experimental muscular dystrophy drug, sevasemten, has failed to meet its primary and secondary endpoints, dealing a significant blow to the French pharmaceutical company’s nascent neuromuscular strategy just months after a major acquisition.

Servier announced after Tuesday’s market close that the treatment showed no statistically significant benefit on a functional rating scale measuring muscle movement during activities such as standing and walking. The drug also missed all secondary goals in the trial, known as GRAND CANYON. The company provided no specific efficacy data in its brief statement.

Becker muscular dystrophy, a rare genetic disorder caused by a deficiency of the muscle-protecting protein dystrophin, currently has no FDA-approved therapies. Sevasemten is a small molecule designed to inhibit fast skeletal muscle troponin, a protein that drives rapid muscle fiber contractions linked to muscle damage. By blocking this target, the drug aims to preserve muscle function.

The failure contrasts with earlier results from the Phase 2 CANYON study, where sevasemten successfully reduced a biomarker of skeletal muscle damage at 12 months. GRAND CANYON was an expanded, pivotal cohort that evaluated the drug over an 18-month period.

“The results of the pivotal GRAND CANYON study are not aligned with certain observations made in previous clinical studies, including the Phase 2 CANYON study,” Servier stated. The company said it is conducting a comprehensive analysis of the GRAND CANYON dataset alongside prior clinical data to understand the discrepancy.

That analysis will be critical for assessing potential readthrough to Duchenne muscular dystrophy, a more severe condition also rooted in dystrophin deficiency. A separate mid-stage trial of sevasemten in Duchenne patients remains ongoing.

Sevasemten originated from Edgewise Therapeutics, which ran the Phase 2 program. In June, Servier acquired Edgewise’s muscular dystrophy portfolio for $1.55 billion upfront, with up to $1.1 billion in potential milestones, including $200 million tied to regulatory approval for Becker. The deal represented Servier’s first late-stage investment in rare neuromuscular disease.

Frederic Scaerou, Servier’s global head of business development, had described the asset as a “late-stage anchor” for building a broader neuromuscular franchise at the BIO International Convention in June. He indicated that success would trigger further investment across Phase 3, Phase 2, Phase 1, and preclinical programs in the same therapeutic area.

The Edgewise transaction was Servier’s second major deal of the year, following a $2.5 billion agreement in March to acquire Day One Biopharmaceuticals for its commercialized brain cancer drug and antibody-drug conjugate pipeline. The acquisitions align with Servier’s strategy to grow annual revenue to €10 billion (approximately $11.6 billion) by 2030. The privately held company reported €6 billion (about $8 billion) in revenue for the fiscal year ended September 30, 2025.

Photo: Romain Gautier/ Hans Lucas/AFP, via Getty Images

Source link